$RLMD
RELMADA THERAPEUTICS, INC.

2023 Q4 Form 10-Q Financial Statement

#000121390023084737 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.08M $12.24M
YoY Change 2.06% 49.12%
% of Gross Profit
Research & Development $14.75M $10.45M
YoY Change -45.1% -65.76%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $26.83M $22.69M
YoY Change -30.68% -41.42%
Operating Profit -$22.69M
YoY Change -41.42%
Interest Expense $1.664M $690.0K
YoY Change 119.53% -201.24%
% of Operating Profit
Other Income/Expense, Net $0.00 $690.6K
YoY Change -201.33%
Pretax Income -$25.17M -$22.00M
YoY Change -33.68% -44.19%
Income Tax
% Of Pretax Income
Net Earnings -$25.17M -$22.00M
YoY Change -33.68% -44.18%
Net Earnings / Revenue
Basic Earnings Per Share -$0.73
Diluted Earnings Per Share -$0.84 -$1.31
COMMON SHARES
Basic Shares Outstanding 30.10M shares 30.10M shares
Diluted Shares Outstanding 30.10M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $96.32M $106.3M
YoY Change -35.06% -42.28%
Cash & Equivalents $4.092M $6.699M
Short-Term Investments $92.23M $99.60M
Other Short-Term Assets $1.185M $2.800M
YoY Change -70.63% -5.2%
Inventory
Prepaid Expenses $1.185M $2.834M
Receivables
Other Receivables
Total Short-Term Assets $97.51M $109.1M
YoY Change -36.21% -41.69%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $43.13K $47.72K
YoY Change 23.67% 196.46%
Total Long-Term Assets $43.12K $47.72K
YoY Change 23.64% 196.46%
TOTAL ASSETS
Total Short-Term Assets $97.51M $109.1M
Total Long-Term Assets $43.12K $47.72K
Total Assets $97.55M $109.1M
YoY Change -36.2% -41.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.506M $2.857M
YoY Change -33.37% -72.6%
Accrued Expenses $8.689M $5.565M
YoY Change 20.56% -46.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.19M $8.422M
YoY Change -2.2% -59.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.19M $8.422M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $12.19M $8.400M
YoY Change -2.2% -59.57%
SHAREHOLDERS EQUITY
Retained Earnings -$560.9M -$535.7M
YoY Change 21.38% 26.3%
Common Stock $30.10K $30.10K
YoY Change 0.0% 5.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.36M $100.7M
YoY Change
Total Liabilities & Shareholders Equity $97.55M $109.1M
YoY Change -36.2% -41.67%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$25.17M -$22.00M
YoY Change -33.68% -44.18%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.25M -$11.63M
YoY Change -71.44% -56.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $7.741M $3.860M
YoY Change -567.62% -87.77%
Cash From Investing Activities $7.741M $3.860M
YoY Change -567.62% -87.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -98.46K 0.000
YoY Change -124.02% -100.0%
NET CHANGE
Cash From Operating Activities -10.25M -11.63M
Cash From Investing Activities 7.741M 3.860M
Cash From Financing Activities -98.46K 0.000
Net Change In Cash -2.607M -7.770M
YoY Change -92.98% -247.62%
FREE CASH FLOW
Cash From Operating Activities -$10.25M -$11.63M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30099203 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
RELMADA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5401931
dei Entity Address Address Line1
EntityAddressAddressLine1
2222 Ponce de Leon
dei Entity Address Address Line2
EntityAddressAddressLine2
Floor 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Coral Gables
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33134
dei City Area Code
CityAreaCode
(786)
dei Local Phone Number
LocalPhoneNumber
629-1376
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
RLMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30099203 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6698599 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5395905 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
99568502 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
142926781 usd
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
512432 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2834037 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4035186 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
109101138 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
152870304 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
47715 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
34875 usd
CY2023Q3 us-gaap Assets
Assets
109148853 usd
CY2022Q4 us-gaap Assets
Assets
152905179 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2856752 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5261936 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5565466 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7206941 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8422218 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12468877 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3500000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30099203 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30099203 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30099203 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30099203 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
30099 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
30099 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
636434059 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
602517138 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-535737523 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-462110935 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
100726635 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
140436302 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109148853 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
152905179 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10454072 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30529108 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40055287 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86454632 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12238566 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8208053 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36817686 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36092024 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
22692638 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
38737161 usd
us-gaap Operating Expenses
OperatingExpenses
76872973 usd
us-gaap Operating Expenses
OperatingExpenses
122546656 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22692638 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38737161 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-76872973 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-122546656 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
6351606 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1321441 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
827614 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3892478 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1544898 usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-51714 usd
CY2022Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-561648 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-718422 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-552171 usd
CY2023Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-579147 usd
CY2022Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-947512 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
72329 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3897135 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
690580 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-681546 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3246385 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3447198 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22002058 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-39418707 usd
us-gaap Net Income Loss
NetIncomeLoss
-73626588 usd
us-gaap Net Income Loss
NetIncomeLoss
-119099458 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.04
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099203 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30063735 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30099203 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29470198 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
140436302 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11354466 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-26321576 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
125469192 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11169517 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25302954 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
111335755 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11392938 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22002058 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
100726635 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
208264886 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11930681 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29583542 usd
CY2022Q1 rlmd Warrant Exercised For Cash
WarrantExercisedForCash
300006 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64800 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-39745783 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
210398132 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12295016 usd
CY2022Q2 rlmd Warrant Exercised For Cash
WarrantExercisedForCash
595350 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
352744 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13145057 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-39934968 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
196851331 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8343139 usd
CY2022Q3 rlmd Warrant Exercised For Cash
WarrantExercisedForCash
332916 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
286176 usd
CY2022Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-50000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-39418707 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
166344855 usd
us-gaap Net Income Loss
NetIncomeLoss
-73626588 usd
us-gaap Net Income Loss
NetIncomeLoss
-119099458 usd
us-gaap Share Based Compensation
ShareBasedCompensation
33916921 usd
us-gaap Share Based Compensation
ShareBasedCompensation
32568836 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-718422 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-552171 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
72329 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3897135 usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-86377 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-512432 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1188309 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-8359994 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2405184 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-766661 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1641475 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6482889 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41409492 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67918717 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
57151963 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
38993173 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
99864149 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
60382229 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42712186 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21389056 usd
rlmd Payment Of Fees For Warrants Issued For Common Stock
PaymentOfFeesForWarrantsIssuedForCommonStock
50000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42728599 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
703720 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1228272 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44610591 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1302694 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1919070 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5395905 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44443439 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6698599 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42524369 usd
rlmd Cash Less Share Exchange For Prefunded Warrants
CashLessShareExchangeForPrefundedWarrants
1452 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – BUSINESS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relmada Therapeutics, Inc. (Relmada or the Company) (a Nevada corporation), is a clinical-stage, publicly traded biotechnology company focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with the Food and Drug Administration (FDA) and other governmental regulations and approval requirements.</span></p>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41409492 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-535737523 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses and recorded amounts related to income taxes.</span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6698599 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
99568502 usd
CY2023Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-579147 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
72329 usd
CY2022Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-947512 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3897135 usd
CY2022Q4 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
529800 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15483009 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15204298 shares
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
445100 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
313200 usd
CY2023Q3 rlmd Prepaid Research And Development
PrepaidResearchAndDevelopment
2185900 usd
CY2022Q4 rlmd Prepaid Research And Development
PrepaidResearchAndDevelopment
3619800 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
203000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
102200 usd
CY2023Q3 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
2834000 usd
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
4035200 usd
CY2023Q3 rlmd Accrued Research And Development
AccruedResearchAndDevelopment
3860700 usd
CY2022Q4 rlmd Accrued Research And Development
AccruedResearchAndDevelopment
5809800 usd
CY2023Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
174900 usd
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
116500 usd
CY2023Q3 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
1106900 usd
CY2022Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
492100 usd
CY2023Q3 us-gaap Accrued Vacation Current And Noncurrent
AccruedVacationCurrentAndNoncurrent
355900 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
67100 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
258700 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
5565500 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
7206900 usd
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5152942 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1500000 shares
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3900000 shares
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2500000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
13052942 shares
rlmd Stock Options Exercisable Period
StockOptionsExercisablePeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
597374 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q3 rlmd Stock Based Compensation Expense
StockBasedCompensationExpense
1200000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
61200000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P2Y3M29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12122606 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
417998 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
690000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.52
rlmd Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1
P9Y3M29D
rlmd Aggregate Intrinsic Value Outstanding And Expected To Vest Granted1
AggregateIntrinsicValueOutstandingAndExpectedToVestGranted1
14600 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
191099 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
165939 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12455568 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.2
rlmd Weighted Average Remaining Contractual Term Years Ending Balance1
WeightedAverageRemainingContractualTermYearsEndingBalance1
P7Y10M9D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14600 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6559124 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
20.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M1D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
3027441 shares
CY2022Q4 rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare
15.24
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
3027441 shares
CY2023Q3 rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShare
15.24
rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsVested
2853816 shares
rlmd Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price Per Share Warrants Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePricePerShareWarrantsVested
16.08
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3950000 usd
CY2023Q3 rlmd Intrinsic Value Of Warrant Vested And Outstanding
IntrinsicValueOfWarrantVestedAndOutstanding
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33916900 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32568800 usd
CY2023Q3 rlmd Payment For License
PaymentForLicense
45000 usd
CY2021Q3 us-gaap Payments For Fees
PaymentsForFees
12700000 usd
CY2021Q3 rlmd Milestone Payment
MilestonePayment
160000000 usd
CY2021Q3 us-gaap Payments For Rent
PaymentsForRent
11000 usd
rlmd Lease Period
LeasePeriod
P5M
CY2022 us-gaap Payments For Rent
PaymentsForRent
9000 usd
us-gaap Payments For Rent
PaymentsForRent
14500 usd
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-12-31
us-gaap Sales Type Lease Initial Direct Cost Expense Commencement
SalesTypeLeaseInitialDirectCostExpenseCommencement
213500 usd
us-gaap Sales Type Lease Initial Direct Cost Expense Commencement
SalesTypeLeaseInitialDirectCostExpenseCommencement
87100 usd
CY2017Q2 us-gaap Proceeds From Fees Received
ProceedsFromFeesReceived
7529 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
493452 usd
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
397049 usd
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0838 pure
CY2023Q3 rlmd Sale Type Lease Of Fixed Assets
SaleTypeLeaseOfFixedAssets
96403 usd
us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%.
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
118800 usd
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
87900 usd
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
rlmd Payment Of Fees For Warrants Issued For Common Stock
PaymentOfFeesForWarrantsIssuedForCommonStock
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
rlmd Cash Less Share Exchange For Prefunded Warrants
CashLessShareExchangeForPrefundedWarrants
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
rlmd Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1
rlmd Aggregate Intrinsic Value Outstanding And Expected To Vest Forfeited1
AggregateIntrinsicValueOutstandingAndExpectedToVestForfeited1
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
rlmd Weighted Average Remaining Contractual Term Years Cancelled
WeightedAverageRemainingContractualTermYearsCancelled
rlmd Aggregate Intrinsic Value Cancelled
AggregateIntrinsicValueCancelled
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001553643

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001213900-23-084737-index-headers.html Edgar Link pending
0001213900-23-084737-index.html Edgar Link pending
0001213900-23-084737.txt Edgar Link pending
0001213900-23-084737-xbrl.zip Edgar Link pending
f10q0923ex31-1_relmada.htm Edgar Link pending
f10q0923ex31-2_relmada.htm Edgar Link pending
f10q0923ex32-1_relmada.htm Edgar Link pending
f10q0923ex32-2_relmada.htm Edgar Link pending
f10q0923_relmadatherap.htm Edgar Link pending
f10q0923_relmadatherap_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlmd-20230930.xsd Edgar Link pending
Show.js Edgar Link pending
rlmd-20230930_def.xml Edgar Link unprocessable
rlmd-20230930_lab.xml Edgar Link unprocessable
rlmd-20230930_pre.xml Edgar Link unprocessable
rlmd-20230930_cal.xml Edgar Link unprocessable